Ob/Gyn Medical News about estrogen positive breast cancer;letrozole and anastrozole

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women
Breast Cancer Research and Treatment, 05/15/08

Murray J et al. – In breast cancer treatment, both letrozole and anastrozole (14-day treatment) reduce proliferation and estrogen receptor (ER) and progesterone receptor (PgR) expression

Methods

Study to compare changes in proliferation following 14 days of treatment with anastrozole and letrozole
Randomization of 206 women with 209 ER-positive operable breast cancers (3 bilateral) to either 14-day treatment with 2.5 mg of letrozole or 1 mg of anastrozole prior to surgery
Analysis of changes in ER and PgR expression assessed by ALLRED scores and proliferation by Ki67
Combination of Hercept test and FISH to assess tumor HER2 status

Results

Both letrozole and anastrozole reduced ER expression (ALLRED score) by a mean of 0.32 and PgR by a mean of 2.54
Proliferation reduced by letrozole from mean of 6.37% to 0.81%; by anastrozole from 5.81% to 0.77%
Drugs showed no differences in decrease in ER, PgR, or proliferation
Both letrozole and anastrozole produced significant falls in proliferation in both HER2-positive and -negative cancers

<< Previous
A pilot genome-wide association study of early-onset breast...

Next >>
Optimal delivery of anthracycline-based chemotherapy in the...